Increasing Hepatitis B Screening Among Korean Church Attendees
NCT ID: NCT00760721
Last Updated: 2016-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1123 participants
INTERVENTIONAL
2006-09-30
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators will design a culturally specific intervention (educational sessions) and test the effect of the intervention on 1200 Korean Americans.
All subjects will be interviewed before the intervention/control sessions and 6 months after the sessions to assess HBV screening levels in the two groups. Self-reported HBV screening will be verified by a review of subjects' medical records.
The primary study hypothesis is that the intervention group will have a higher rate of HBV serologic testing at follow-up compared to the control group.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators will design a culturally specific intervention; an educational small group discussion led by a trained Korean leader. The effect of the intervention will be tested on 1200 Korean Americans.
Subjects will be recruited at Korean churches and invited to join a one-hour discussion of health issues with other members of their church. One half of the subjects will participate in the intervention group. These subjects will discuss HBV and will receive resources related to HBV and where to obtain screening. The other half of the subjects will participate in the control group. These subjects will discuss nutrition and physical activity and will receive resources related to these topics, but not related to HBV and where to obtain screening.
All subjects will be interviewed before the sessions and 6 months after the sessions to assess HBV screening levels in the two groups. Self-reported HBV screening will be verified by a review of subjects' medical records.
The primary study hypothesis is that the intervention group will have a higher rate of HBV serologic testing at follow-up compared to the control group.
Secondary hypotheses are:
The intervention group will have a higher level of knowledge of hepatitis B and liver cancer at follow-up compared to the control group.
The effect of the intervention on hepatitis B serologic testing will be mediated by knowledge of hepatitis B and liver cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Educational small group session with HBV screening resources provided
Educational Small Group Session
1 hour small group health-related discussion
2
Educational small group discussion, diet/physical activity resources provided
Educational Small Group Session
1 hour small group health-related discussion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Educational Small Group Session
1 hour small group health-related discussion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have not previously received HBV screening or do not know the results of previous HBV screening test
* No history of liver cancer or liver disease
* Current resident of the Los Angeles area
Exclusion Criteria
* Not of Korean ancestry
* Previously screened for HBV
* History of liver disease or liver cancer
* Not a current resident of the Los Angeles area
18 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
National Cancer Institute (NCI)
NIH
University of California, Los Angeles
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roshan Bastani, PhD
Role: PRINCIPAL_INVESTIGATOR
University of California, Los Angeles
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA, Division of Cancer Prevenion and Control Research
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.